Comparison
Tesamorelin vs CJC-1295: A Research Comparison
A research-focused comparison of tesamorelin and CJC-1295 — GHRH analogues differing in sequence length, modification and pharmacokinetic behaviour.
Quick Answer
Tesamorelin and CJC-1295 are both growth hormone–releasing hormone (GHRH) analogues studied for the promotion of growth hormone release. They differ in sequence — tesamorelin derives from the full 44-amino-acid native GHRH while CJC-1295 is a shorter modified analogue — and in modification, with CJC-1295 with DAC carrying an albumin-binding group for extended duration.
Tesamorelin and CJC-1295 are both synthetic peptides in the growth hormone–releasing hormone (GHRH) analogue family. They share a receptor target and a research context, but differ in their sequences, their modifications, and their pharmacokinetic behaviour.
This page is a non-promotional scientific reference for researchers. It does not provide fat-loss, performance, anti-ageing, therapeutic, or human-use guidance. Both compounds supplied by Bulk Aussie Peptides are for laboratory research purposes only.
At a Glance
Both compounds engage the GHRH receptor and are studied for the promotion of growth hormone release. Tesamorelin is engineered from the 44-amino-acid native GHRH for improved stability, while CJC-1295 is a modified GHRH analogue that — in its "with DAC" form — carries an albumin-binding Drug Affinity Complex for extended duration.
Compare the Two Compounds
- Compound class: both are GHRH analogues.
- Receptor target: the GHRH receptor in both cases.
- Sequence basis: tesamorelin is derived from the full 44-amino-acid native GHRH; CJC-1295 is a shorter modified analogue.
- Modification & duration: tesamorelin is stability-modified; CJC-1295 with DAC carries an albumin-binding group that extends its circulating duration.
- Research focus: both address growth hormone release, but through different modification profiles.
Why the Difference Matters in Research
While the two compounds converge on the same receptor, their different lengths and modifications mean they are not equivalent. Choosing between them in research design depends on the desired sequence and pharmacokinetic profile rather than a simple substitution. Findings remain preclinical.
Analytical Testing
Both are characterised using HPLC for purity and mass spectrometry for identity confirmation. See how to read a peptide Certificate of Analysis.
Individual References
- Tesamorelin research reference
- CJC-1295 with DAC research reference
- CJC-1295 without DAC research reference
About this page. This article is a non-promotional reference prepared by the Bulk Aussie Peptides research team for educational purposes. It is not medical advice and does not provide dosage, injection, therapeutic, or human-use guidance. Product information is for laboratory research only. How we write and review our research library · Report a correction
Related Articles
Individual Compound Research
Tesamorelin: A Laboratory Research Reference
A non-promotional scientific reference on tesamorelin — GHRH analogue identity, GHRH receptor pharmacology, molecular characteristics and analytical testing.
Individual Compound Research
CJC-1295 with DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 with DAC — GHRH analogue identity, the Drug Affinity Complex modification, molecular characteristics and analytical testing.
Individual Compound Research
CJC-1295 without DAC: A Laboratory Research Reference
A non-promotional scientific reference on CJC-1295 without DAC — unmodified GHRH analogue identity, molecular characteristics, mechanism as studied and analytical testing.
Explore the Research Library
Browse our collection of educational reference material.
View All Articles